Hepatocellular carcinoma surveillance: current practice and future directions

Abstract

Hepatocellular carcinoma (HCC) is among the leading causes of cancer incidence and mortality worldwide. Surveillance of individuals with cirrhosis or other conditions that confer a high risk of HCC development is essential for early detection and improved overall survival. Biannual ultrasonography with or without alpha-fetoprotein is widely recommended as the standard method for HCC surveillance, but it has limited sensitivity in early disease and may be inadequate in certain individuals. This review article will provide a comprehensive overview of the current landscape of HCC surveillance, including the rationale and indications for HCC surveillance, standard methods for HCC surveillance, and their strengths/limitations. Alternative surveillance methods such as the role of cross-sectional imaging, emerging circulating biomarkers, as well as the problem of under-utilization of HCC surveillance and surveillance-related harms will also be discussed in this review.

Keywords

Hepatocellular carcinoma / surveillance / cirrhosis / hepatitis B virus / alpha-fetoprotein / liquid biopsy / under-utilization

References

[1] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[2] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[3] Petrick JL,Znaor A.International trends in hepatocellular carcinoma incidence, 1978-2012.Int J Cancer2020;147:317-30 PMCID:PMC7470451

[4] Chen J,Lu L,Shen A.Liver cancer screening in China: practices and its extended questions.HR2019;2019

[5] Zheng R,Zhang S.Liver cancer incidence and mortality in China: temporal trends and projections to 2030.Chin J Cancer Res2018;30:571-9 PMCID:PMC6328503

[6] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[7] Asrani SK,Arab JP.Reducing the global burden of alcohol-associated liver disease: a blueprint for action.Hepatology2021;73:2039-50

[8] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[9] Yang JD.New advances in the diagnosis and management of hepatocellular carcinoma.BMJ2020;371:m3544

[10] Cillo U,Grigoletto F.Prospective validation of the Barcelona Clinic Liver Cancer staging system.J Hepatol2006;44:723-31

[11] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[12] Finn RS,Farah W.Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis.Hepatology2018;67:422-35

[13] Chen JG,Chen QG.Screening for liver cancer: results of a randomised controlled trial in Qidong, China.J Med Screen2003;10:204-9

[14] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004;130:417-22

[15] Poustchi H,Strasser SI,McCaughan GW.Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?.Hepatology2011;54:1998-2004

[16] Naimark D,Detsky AS.The meaning of life expectancy: what is a clinically significant gain?.J Gen Intern Med1994;9:702-7

[17] Laupacis A,Detsky AS.How attractive does a new technology have to be to warrant adoption and utilization?.CMAJ1992;146:473-81 PMCID:PMC1488412

[18] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[19] Lin OS,Sanders GD.Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.Aliment Pharmacol Ther2004;19:1159-72

[20] Yang JD,Piscitello AJ.Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.Hepatology2018;68:78-88 PMCID:PMC5897179

[21] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018;68:723-50

[22] Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[23] Omata M,Kokudo N.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Hepatol Int2017;11:317-70 PMCID:PMC5491694

[24] Bréchot C.Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.Gastroenterology2004;127:S56-61

[25] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol2016;64:800-6

[26] Yang M,Liu H.Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States.Sci Rep2020;10:20922 PMCID:PMC7708980

[27] Xie DY,Zhou J,Gao Q.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.Hepatobiliary Surg Nutr2020;9:452-63 PMCID:PMC7423548

[28] Loomba R,Patton H.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.Gastroenterology2020;158:1822-30 PMCID:PMC8012107

[29] Dalton-Fitzgerald E,Kandunoori P,Yopp A.Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2015;13:791-8.e1 PMCID:PMC4289665

[30] McGowan CE,Luong MU.Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers.Clin Gastroenterol Hepatol2015;13:799-804 PMCID:PMC4458065

[31] Farvardin S,Khambaty M.Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.Hepatology2017;65:875-84 PMCID:PMC5568252

[32] Singal AG,Tiro J.Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.Am J Med2015;128:90.e1-7 PMCID:PMC4282818

[33] Wolf E,Marrero JA,Singal AG.Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis.Hepatology2021;73:713-25 PMCID:PMC7648722

[34] Xu K,Rochling FA.Practice, knowledge, and barriers for screening of hepatocellular carcinoma among high-risk Chinese patients.Ann Glob Health2017;83:281-92

[35] Dai J,Du Y,McNeil EB.Adherence to hepatocellular carcinoma surveillance and perceived barriers among high-risk chronic liver disease patients in Yunnan, China.Cancer Manag Res2020;12:6209-20 PMCID:PMC7434375

[36] Im S,Lee JH.Surveillance rate and its impact on survival of hepatocellular carcinoma patients in South Korea: a cohort study.Cancer Res Treat2019;51:1357-69 PMCID:PMC6790861

[37] Atiq O,Yopp AC.An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis.Hepatology2017;65:1196-205 PMCID:PMC5659110

[38] Konerman MA,Zhao B,Lok AS.Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program.Liver Transpl2019;25:369-79 PMCID:PMC6395491

[39] Singal AG,Obi J.Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis.Clin Gastroenterol Hepatol2021;19:1925-32.e1 PMCID:PMC7943645

[40] Harris PS,Gray ME,McGuire BM.Hepatocellular carcinoma surveillance: an evidence-based approach.World J Gastroenterol2019;25:1550-9 PMCID:PMC6452232

[41] Simmons O,Yokoo T.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[42] Hong SB,Choi SH.Inadequate ultrasound examination in hepatocellular carcinoma surveillance: a systematic review and meta-analysis.J Clin Med2021;10:3535 PMCID:PMC8397222

[43] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[44] Sammon J.Hepatocellular carcinoma surveillance: the often-neglected practice.Hepatobiliary Surg Nutr2019;9:77-9 PMCID:PMC7026797

[45] Khalili K.Historical data are not relevant to the diagnostic performance of ultrasound in surveillance for hepatocellular carcinoma.Gastroenterology2019;157:899-900

[46] Khalili K,Kim TK.The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success.Can J Gastroenterol Hepatol2015;29:267-73 PMCID:PMC4467488

[47] Kuo YH,Chen CL.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis.Eur J Cancer2010;46:744-51

[48] Noda I,Nakahara H.Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus.J Gastroenterol2010;45:105-12

[49] Santi V,Gramenzi A.Italian Liver Cancer (ITALI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.J Hepatol2010;53:291-7

[50] Maruyama H,Yokosuka O.Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.J Gastroenterol2016;51:421-33

[51] Kudo M,Kumada T,Tada T.Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma.Am J Gastroenterol2011;106:368-70

[52] Kudo M,Osaki Y.B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial.Liver Cancer2019;8:271-80 PMCID:PMC6738204

[53] Park JH,Lee SJ.Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: a multicenter diagnostic trial (SCAN).Radiology2019;292:638-46

[54] Ahmed Mohammed HF.Should AFP (or any biomarkers) be used for HCC surveillance?.Curr Hepatol Rep2017;16:137-45 PMCID:PMC5659201

[55] Song PP,Inagaki Y.Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.World J Gastroenterol2016;22:262-74 PMCID:PMC4698491

[56] Lee E,Singal AG,Volk M.Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time.Clin Gastroenterol Hepatol2013;11:437-40

[57] Gopal P,Waljee AK.Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2014;12:870-7 PMCID:PMC3975698

[58] Yang JD,Singal AG.Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase.Cancer Epidemiol Biomarkers Prev2017;26:1085-92 PMCID:PMC5519351

[59] Pocha C,McMaken KA,Thuras P.Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study.Aliment Pharmacol Ther2013;38:303-12

[60] Kim SY,Lim YS.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma.JAMA Oncol2017;3:456-63 PMCID:PMC5470420

[61] Kim HL,Park JA,Lim YS.Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis.Hepatology2019;69:1599-613

[62] Besa C,Pandharipande PV.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.Abdom Radiol (NY)2017;42:179-90

[63] Marks RM,Heba ER.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.AJR Am J Roentgenol2015;204:527-35

[64] Li D,Satomura S.AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.Clinica Chimica Acta2001;313:15-9

[65] Marrero JA,Wei W.Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.Hepatology2003;37:1114-21

[66] Park H,Park JY.Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.Liver Int2014;34:313-21

[67] Johnson PJ,Cox TF.The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.Cancer Epidemiol Biomarkers Prev2014;23:144-53

[68] Berhane S,Tada T.Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients.Clin Gastroenterol Hepatol2016;14:875-886.e6

[69] Yang JD,Mara KC.GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score.Cancer Epidemiol Biomarkers Prev2019;28:531-8 PMCID:PMC6401221

[70] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-35.e4

[71] Roberts LR.Current status of the GALAD and BALAD biomarker models for hepatocellular carcinoma.Gastroenterol Hepatol (N Y)2019;15:672-5 PMCID:PMC6935027

[72] Ye Q,Zheng S.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Mol Cancer2019;18:114 PMCID:PMC6607541

[73] Ahn JC,Chen PJ.Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma.Hepatology2021;73:422-36 PMCID:PMC8183673

[74] Kalinich M,Kwan TT.An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.Proc Natl Acad Sci U S A2017;114:1123-8 PMCID:PMC5293050

[75] Yang JD,Kisiel JB.Circulating Tumor DNA and hepatocellular carcinoma.Semin Liver Dis2019;39:452-62

[76] Oussalah A,Bensenane M.Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma.EBioMedicine2018;30:138-47 PMCID:PMC5952996

[77] Chalasani NP,Bhattacharya A.A novel blood-based panel of methylated DNA and Protein markers for detection of early-stage hepatocellular carcinoma.Clin Gastroenterol Hepatol2021;19:2597-2605.e4

[78] Xu RH,Krawczyk M.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.Nat Mater2017;16:1155-61

[79] Tran NH,Roberts LR.Using cell-free DNA for HCC surveillance and prognosis.JHEP Rep2021;3:100304 PMCID:PMC8182265

[80] Singal AG,Pinato DJ.International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma.Gastroenterology2021;160:2572-84 PMCID:PMC8169638

[81] Lee YT,Wang JJ.The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma.Cancers (Basel)2021;13:3076 PMCID:PMC8233859

[82] Sun N,Zhang RY.Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.Nat Commun2020;11:4489 PMCID:PMC7477161

[83] von Felden J,Dogra N.Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer.Gut2021; PMCID:PMC8795201

[84] Ahn JC,Simonetto DA,Shah VH.Application of artificial intelligence for the diagnosis and treatment of liver diseases.Hepatology2021;73:2546-63

[85] Ioannou GN,Beste LA.Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis.JAMA Netw Open2020;3:e2015626 PMCID:PMC7489819

[86] Phan DV,Li AA,Nguyen VC.Liver cancer prediction in a viral hepatitis cohort: a deep learning approach.Int J Cancer2020;147:2871-8

[87] Nam JY,Bae J,Kim JW.Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy.JHEP Rep2020;2:100175 PMCID:PMC7581930

[88] Schmauch B,Jehanno P.Diagnosis of focal liver lesions from ultrasound using deep learning.Diagn Interv Imaging2019;100:227-33

[89] Brehar R,Vancea F.Comparison of deep-learning and conventional machine-learning methods for the automatic recognition of the hepatocellular carcinoma areas from ultrasound images.Sensors (Basel)2020;20:3085 PMCID:PMC7309124

[90] Jin J,Zhang T.Deep learning radiomics model accurately predicts hepatocellular carcinoma occurrence in chronic hepatitis B patients: a five-year follow-up.Am J Cancer Res2021;11:576-89 PMCID:PMC7868753

[91] Yasaka K,Abe O.Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: a preliminary study.Radiology2018;286:887-96

[92] Shi W,Cao S.Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol.Abdom Radiol (NY)2020;45:2688-97

[93] Hamm CA,Savic LJ.Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI.Eur Radiol2019;29:3338-47 PMCID:PMC7251621

[94] Wang CJ,Savic LJ.Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features.Eur Radiol2019;29:3348-57 PMCID:PMC7243989

[95] Azuaje F.Artificial intelligence for precision oncology: beyond patient stratification.NPJ Precis Oncol2019;3:6 PMCID:PMC6389974